The tumor suppressor kinase DAPK3 drives tumor-intrinsic immunity through the STING-IFNb pathway Phospho
Ontology highlight
ABSTRACT:
INSTRUMENT(S): Orbitrap Fusion
ORGANISM(S): Homo Sapiens (ncbitaxon:9606)
SUBMITTER: 
David Gonzalez
PROVIDER: MSV000086706 | MassIVE | Fri Jan 15 13:09:00 GMT 2021
SECONDARY ACCESSION(S): PXD023637
REPOSITORIES: MassIVE
Similar Datasets
Project description:Proteome analysis reveals that the tumor suppressor kinase DAPK3 drives tumor-intrinsic immunity through the STING-IFNb pathway Proteome
2021-01-15 | MSV000086708 | MassIVE
Project description:Understanding MoA of ceralasertib (AZD6738) in driving efficacy through immune regulation via polymorphonuclear-myeloid derived suppressor cells (PMN-MDSC) and monocytic-myeloid derived suppressor cells (M-MDSC) on tumour intrinsic pathways (STING/IFN) for AZD6738 driven efficacy. Animals were treated only for 7 days and left for further 7 days without treatment. We compared cells against Vehicle and spleen derived ( naive) as a positive control.
2024-01-30 | E-MTAB-13707 | biostudies-arrayexpress
Project description:Drosophila melanogaster Sting, Sting, is differentially expressed in 23 experiment(s);
| FBgn0033453 | ExpressionAtlas
Project description:Drosophila melanogaster Sting, Sting, is expressed in 4 baseline experiment(s);
| FBgn0033453 | ExpressionAtlas
Project description:Evasion of host immunity is a hallmark of cancer; however, mechanisms linking oncogenic mutations and immune escape are incompletely understood. Through loss-of-function screening of 1,001 tumor suppressor genes, we identified death-associated protein kinase 3 (DAPK3) as a previously unrecognized driver of anti-tumor immunity through the stimulator of interferon genes (STING) pathway of cytosolic DNA sensing. Loss of DAPK3 expression or kinase activity impaired STING activation and interferon (IFN)-β-stimulated gene induction. DAPK3 deficiency in IFN-β-producing tumors drove rapid growth and reduced infiltration of CD103+CD8α+ dendritic cells and cytotoxic lymphocytes, attenuating the response to cancer chemo-immunotherapy. Mechanistically, DAPK3 coordinated post-translational modification of STING. In unstimulated cells, DAPK3 inhibited STING K48-linked poly-ubiquitination and proteasome-mediated degradation. After cGAMP stimulation, DAPK3 was required for STING K63-linked poly-ubiquitination and STING-TANK-binding kinase 1 interaction. Comprehensive phospho-proteomics uncovered a DAPK3-specific phospho-site on the E3 ligase LMO7, critical for LMO7-STING interaction and STING K63-linked poly-ubiquitination. Thus, DAPK3 is an essential kinase for STING activation that drives tumor-intrinsic innate immunity and tumor immune surveillance.
| S-EPMC8300883 | biostudies-literature
Project description:Esophageal cancer (ESCA) is one of the most common gastrointestinal malignancies. Recently, immunotherapy has been successfully applied for cancer treatment. However, the overall response rate of immunotherapy in ESCA patients is low and most patients may develop drug resistance. High mobility group A1 (HMGA1) is a chromatin remodeling protein, which participates in the regulation of a variety of biological processes and promotes tumor progression. The role of HMGA1 in anti-tumor immunity, especially that in esophageal squamous cell carcinoma (ESCC), remains largely unknown. Herein, we demonstrate that HMGA1 inhibited the expression of the stimulator of interferon genes (STING), inactivated the secretion of type I IFNs (T1IFNs), downregulated interferon stimulating genes (ISGs), and suppressed the recruitment of tumor infiltrating lymphocytes (TILs) that improve anti-tumor immunity. Mechanistically, we further characterized that HMGA1 decreased the transcription of STING by competing with the transcription coactivator CBP/p300 to bind to cAMP response element binding protein (CREB). Knockdown of HMGA1 promoted the expression of STING, activated IRF3 signaling downstream of TBK1, and hence enhanced the production of T1IFNs. We further demonstrated that the role of HMGA1 in anti-tumor immunity was mediated by STING with orthotopic esophageal carcinoma models in Hmga1flox/floxK14 conditional knock-out, Sting knock-out (Sting-/-), and Hmga1flox/floxK14Sting-/- double knock-out mice. ESCC developed in Hmga1flox/floxK14 conditional knock-out mice possessed widely distributed TILs and were sensitive to STING agonists. In contrast, ESCC generated in Hmga1KI/KIK14 gene knock-in mice or Hmga1flox/floxK14Sting-/- were mostly “cold tumors” with much less TILs and were insensitive to STING agonists. Further, analysis of ESCC tissues from patients confirmed the negative correlation between HMGA1 expression and STING and T lymphocyte infiltration. Moreover, based on the binding pocket of HMGA1, we designed and synthesized a series of HMGA1 inhibitors and characterized that a perylene based nanoparticle PDIC-DPC bore a strong inhibitory effect on HMGA1 and promotes T lymphocyte infiltration. Together, we conclude that oncogenic HMGA1 promotes the tumorigenesis of ESCC by inhibiting STING-mediated antitumor immune. Targeting HMGA1 provides a new strategy for immunotherapy of esophageal cancer.
2025-03-05 | GSE263439 | GEO
Project description:Given that TREX1-deficient tumor cells showed a growth delay in immunocompetent but not immunodeficient hosts, we characterize the consequences of CT26 tumor-intrinsic TREX1 loss on the host immune system by performing single-cell RNA sequencing on intra-tumoral immune cells sorted from control and TREX1 KO CT26 tumors.
2024-03-12 | E-MTAB-13823 | biostudies-arrayexpress
Project description:Metastatic relapse frequently develops from disseminated cancer cells that remain dormant in distant organs after the apparently successful treatment of a primary tumor. Disseminated cancer cells fluctuate between immune evasive quiescent and cell cycle reentry states, which exposes them to elimination by the immune system. Little is known about the molecules that determine immune-mediated clearing of awakened metastatic cells and how this process could be therapeutically activated to eliminate residual disseminated disease in patients. Here, we use models of indolent metastasis to identify cancer cell-intrinsic determinants of immune reactivity during cancer cell exit from dormancy. Through in vivo genetic screens of tumor-intrinsic immune regulators, we identified the STING (stimulator of interferon genes) pathway as a suppressor of metastatic outbreak in dormant models of human and mouse lung adenocarcinoma metastasis. STING levels and signaling activity rise in metastatic progenitors that reenter the cell cycle and are dampened by STING enhancer hypermethylation in breakthrough metastases or enhancer chromatin repression in cells reentering dormancy in response to TGF-β. STING expression in cancer cells from spontaneous metastases suppresses their outgrowth in a NK cell- and CD8+ T cell-dependent manner. Systemic treatment of mice with pharmacologic STING agonists eliminates indolent metastatic cells and prevents spontaneous metastasis, both effects requiring cancer cell STING function. Thus, STING signaling represents a checkpoint against the progression of dormant metastasis and suggests a therapeutically actionable strategy for the prevention of disease relapse. Chromatin immunoprecipitation DNA-sequencing (ChIP-seq) for histone modification markers H3K4me1, H3K4me3, H3K27ac in human lung cancer cells at different stages of metastasis and in cells treated with TGF-β or not.
2023-01-30 | GSE210946 | GEO
Project description:Ionizing radiation promotes cytosolic DNA sensing and consequent antitumor immune responses. But how tumor cell-intrinsic cytosolic DNA sensing is initiated by radiation remains poorly defined. Here, we demonstrated that STING-mediated type I interferon production in tumor cells after radiation relied on the engagement of MLKL-mediated necroptosis, which was elicited by the ZBP1-RIPK3 signaling axis. Physiologically, tumor cell-intrinsic ZBP1-MLKL cascade augmented antitumor immune responses after radiation largely by regulating STING signaling. Mechanistically, ZBP1-MLKL-dependent necroptosis maintained the enrichment of mitochondria DNA inside the cytosol of tumor cells after radiation in a cell-density dependent fashion, contributing to type I interferon responses. In contrast, ablation of caspase-8 unleashed ZBP1-MLKL cascade to gain enhanced cytosolic DNA sensing, and in turn potentiated therapeutic effects of radiation. Thus, our findings uncover an unanticipated mechanism that ZBP1-MLKL-dependent necroptosis drives cytosolic DNA sensing-mediated antitumor immunity after radiation, and provide new strategy to improve radiotherapy by inhibiting caspase-8 cascade.
2021-10-13 | GSE168016 | GEO
Project description:PARP inhibitors (PARPi) have drastically changed the treatment landscape of advanced ovarian tumors with BRCA mutations. However, the impact of this class of inhibitors in patients with advanced BRCA-mutant breast cancer is relatively modest. Using a syngeneic genetically-engineered mouse model of breast tumor driven by Brca1 deficiency, we show that tumor-associated macrophages (TAMs) blunt PARPi efficacy both in vivo and in vitro. Mechanistically, BRCA1-deficient breast tumor cells induce pro-tumor polarization of TAMs, which in turn suppress PARPi-elicited DNA damage in tumor cells, leading to reduced production of dsDNA fragments and synthetic lethality, hence impairing STING-dependent anti-tumor immunity. STING agonists reprogram M2-like pro-tumor macrophages into an M1-like anti-tumor state in a macrophage STING-dependent manner. Systemic administration of a STING agonist breaches multiple layers of tumor cell-mediated suppression of immune cells, and synergizes with PARPi to suppress tumor growth. The therapeutic benefits of this combination require host STING and are mediated by a type I IFN response and CD8+ T cells, but do not rely on tumor cell-intrinsic STING. Our data illustrate the importance of targeting innate immune suppression to facilitate PARPi-mediated engagement of anti-tumor immunity in breast cancer.
2022-04-21 | GSE201017 | GEO